EIF2AK4 (Gene)

Organism:

Homo sapiens

Synonyms:EIF2AK4, ENTREZ:440275, GCN2, HGNC:19687, MIM:609280, NM_001013703, NP_001013725, PVOD2, eukaryotic translation initiation factor 2 alpha kinase 4

Omim:OMIM:609280

Id:ENSG00000128829

Hgnc:HGNC:19687

Entrez:440275

Ensembl:ENSG00000128829

Description:eukaryotic translation initiation factor 2 alpha kinase 4

This gene encodes a member of a family of kinases that phosphorylate the alpha subunit of eukaryotic translation initiation factor-2 (EIF2), resulting in the downregulaton of protein synthesis. The encoded protein responds to amino acid deprivation by binding uncharged transfer RNAs. It may also be activated by glucose deprivation and viral infection. Mutations in this gene have been found in individuals suffering from autosomal recessive pulmonary venoocclusive-disease-2. [provided by RefSeq, Mar 2014]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View EIF2AK4's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with EIF2AK4.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using EIF2AK4.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for EIF2AK4.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with EIF2AK4.

Results found

Linked to

	Label	Description
	GSE150244 TRIM8 knockout 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE186471 1 V 2 CARNOSOL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE208634 1 V 2 DOXYCYCLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 0 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 14 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 1 V 3 PROGESTERONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE102467 3 V 2 PAZOPANIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 1 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE150244 TRIM8 knockout 3 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE186471 1 V 2 CARNOSOL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE208634 1 V 2 DOXYCYCLINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE172016 2 V 0 PACLITAXEL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE261563 CX-5461 6 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 14 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE220806 1 V 3 PROGESTERONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE102467 3 V 2 PAZOPANIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 crizotinib 1 v 10 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.